Schedule 13D ownership disclosure

BRIDGEBIO PHARMA INC

Common Stock, par value $0.001 per share · CUSIP: 10806X102

Event date: 2026-02-12

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • VIKING GLOBAL INVESTORS LPReported CIK 0001103804

    Shares: 13,026,367 · Class: 6.8%

  • Viking Global Opportunities Parent GP LLCReported CIK 0001886738

    Shares: 13,026,367 · Class: 6.8%

  • Viking Global Opportunities GP LLCReported CIK 0001629476

    Shares: 13,026,367 · Class: 6.8%

  • Viking Global Opportunities Portfolio GP LLCReported CIK 0001629472

    Shares: 13,026,367 · Class: 6.8%

  • Viking Global Opportunities Illiquid Investments Sub-Master LPReported CIK 0001629482

    Shares: 13,026,367 · Class: 6.8%

  • HALVORSEN OLE ANDREASReported CIK 0001133006

    Shares: 13,026,367 · Class: 6.8%

  • Ott David C.Reported CIK 0001621842

    Shares: 13,026,367 · Class: 6.8%

  • Shabet Rose SharonReported CIK 0001711393

    Shares: 13,026,367 · Class: 6.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000905148-26-000914
Form type
SCHEDULE 13D/A
Filer
BridgeBio Pharma, Inc.
CIK
CIK 1743881
Filed
Feb 17, 2026
Reporting period
Feb 12, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub